Imagine telling a patient suffering from age-related (type-II) osteoporosis that a single injection of stem cells could restore their normal bone structure. This week, with a publication in STEM CELLS Translational Medicine, a group of researchers from the University of Toronto and The Ottawa Hospital suggest that this scenario may not be too far away.
Osteoporosis affects over 200M people worldwide and, unlike post-menopausal (type-I) osteoporosis, both women and men are equally susceptible to developing the age-related (type-II) form of this chronic disease. With age-related osteoporosis, the inner structure of the bone diminishes, leaving the bone thinner, less dense, and losing its function. The disease is responsible for an estimated 8.9 M fractures per year worldwide. Fractures of the hip—one of the most common breaks for those suffering from type-II osteoporosis—lead to a significant lack of mobility and, for some, can be deadly.
But how can an injection of stem cells reverse the ravages of age in the bones?
Professor William Stanford, senior author of the study, had in previous research demonstrated a causal effect between mice that developed age-related osteoporosis and low or defective mesenchymal stem cells (MSCs) in these animals.
“We reasoned that if defective MSCs are responsible for osteoporosis, transplantation of healthy MSCs should be able to prevent or treat osteoporosis,” said Stanford, who is a Senior Scientist at The Ottawa Hospital and Professor at the University of Ottawa.
To test that theory, the researchers injected osteoporotic mice with MSCs from healthy mice. Stem cells are “progenitor” cells, capable of dividing and changing into all the different cell types in the body. Able to become bone cells, MSCs have a second unique feature, ideal for the development of human therapies: these stem cells can be transplanted from one person to another without the need for matching (needed for blood transfusions, for instance) and without being rejected.
After six months post-injection, a quarter of the life span of these animals, the osteoporotic bone had astonishingly given way to healthy, functional bone.
“We had hoped for a general increase in bone health,” said John E. Davies, Professor at the Faculty of Dentistry and the Institute of Biomaterials & Biomedical Engineering (IBBME) at the University of Toronto, and a co-author of the study. “But the huge surprise was to find that the exquisite inner “coral-like” architecture of the bone structure of the injected animals—which is severely compromised in osteoporosis—was restored to normal.”
The study could soon give rise to a whole new paradigm for treating or even indefinitely postponing the onset of osteoporosis. Currently there is only one commercially available therapy for type-II osteoporosis, a drug that maintains its effectiveness for just two years.
And, while there are no human stem cell trials looking at a systemic treatment for osteoporosis, the long-range results of the study point to the possibility that as little as one dose of stem cells might offer long-term relief.
“It’s very exciting,” said Dr. Jeff Kiernan, first author of the study. A graduate from IBBME who is beginning a Postdoctoral Fellowship at The Ottawa Hospital with the Centre for Transfusion Research, Kiernan pursued the research for his doctoral degree.
“We’re currently conducting ancillary trials with a research group in the U.S., where elderly patients have been injected with MSCs to study various outcomes. We’ll be able to look at those blood samples for biological markers of bone growth and bone reabsorption,” he added.
If improvements to bone health are observed in these ancillary trials, according to Stanford, larger dedicated trials could follow within the next 5 years.
The Latest on: Age-related osteoporosis
via Google News
The Latest on: Age-related osteoporosis
- Elderly Nutrition Market - Competitive Strategy Adopted by Key Players Allergan, Abbott Laboratories, Pfizer, Inc.on October 14, 2019 at 10:09 am
Moreover, the high prevalence of age-related disorders such as neurological disorder ... Moreover, rise in geriatric population, majorly women, in this region is projected to raise the demand for ...
- Bone Degeneration Therapeutics Market Estimated to Grow in Near Future by Players Amgen, Inc., Fate Therapeutics, Inc., Bone Therapeutics SAon October 7, 2019 at 8:44 am
Osteoporosis is characterized by the existence of porous ... treatment of bone voids and other bone defects of the skeletal system caused by trauma or age-related degeneration. Major institutes are ...
- Romosozumab Safe in Osteoporosis With Mild-Moderate Renal Diseaseon October 7, 2019 at 8:26 am
Although CKD is very common in postmenopausal women with osteoporosis, a clinical challenge is that bisphosphonate drugs often ... He also explained that most participants had reduced kidney function ...
- Recommendations to prevent secondary fractures in adults 65+on October 3, 2019 at 5:53 pm
Osteoporosis is a disease of the bones that cause them to weaken and fracture more ... The Marcus Institute carries out rigorous studies that discover the mechanisms of age-related disease and ...
- Statins' dosage can increase or decrease osteoporosis riskon September 30, 2019 at 11:31 am
We found more osteoporosis cases in patients treated with simvastatin ... a promising alternative for treating one of the most common causes of blindness, wet age-related macular degeneration (AMD), ...
- Women over 50 prone to osteoporosis: Doctorson August 30, 2019 at 8:17 pm
Osteoporosis falls into two categories Senile Osteoporosis (age related both in men and women) and postmenopausal osteoporosis (mainly in women). In order to stay healthy and to avoid bone-related ...
- High-Dose Drug Combo Excels in Osteoporosis, but Cost a Barrieron August 28, 2019 at 5:00 pm
Tsai and colleagues explain by way of background that, in contrast with many other chronic, age-related diseases, osteoporosis remains a disease primarily treated with monotherapy. And although the ...
- TGFβ-induced degradation of TRAF3 in mesenchymal progenitor cells causes age-related osteoporosison June 26, 2019 at 2:14 am
We conclude that pharmacologic stabilization of TRAF3 during aging could treat/prevent age-related osteoporosis by inhibiting bone destruction and promoting bone formation.
- Just 1 stem cell injection reverses bone loss in miceon March 16, 2019 at 5:00 pm
Imagine telling someone who suffers from age-related (type II) osteoporosis that just one injection of stem cells could their normal bone structure. Scientists now believe that this scenario may not ...
- Aging and osteoporosis: Take care of your health!on January 11, 2019 at 11:52 pm
Osteoporosis is an age-related change that has the most impact on our lives as we get older. Did you know that osteoporosis is highly treatable and a highly preventative disease? Osteoporosis is very ...
via Bing News